KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Shares Outstanding (Weighted Average): 2011-2025

Historic Shares Outstanding (Weighted Average) for Sarepta Therapeutics (SRPT) over the last 15 years, with Sep 2025 value amounting to $97.7 million.

  • Sarepta Therapeutics' Shares Outstanding (Weighted Average) rose 2.46% to $97.7 million in Q3 2025 from the same period last year, while for Jun 2025 it was $98.3 million, marking a year-over-year increase of 3.97%. This contributed to the annual value of $95.5 million for FY2024, which is 2.11% up from last year.
  • According to the latest figures from Q3 2025, Sarepta Therapeutics' Shares Outstanding (Weighted Average) is $97.7 million, which was down 0.57% from $98.3 million recorded in Q2 2025.
  • Sarepta Therapeutics' Shares Outstanding (Weighted Average)'s 5-year high stood at $98.3 million during Q2 2025, with a 5-year trough of $79.4 million in Q1 2021.
  • For the 3-year period, Sarepta Therapeutics' Shares Outstanding (Weighted Average) averaged around $94.6 million, with its median value being $94.5 million (2024).
  • Data for Sarepta Therapeutics' Shares Outstanding (Weighted Average) shows a peak YoY increased of 10.35% (in 2021) over the last 5 years.
  • Quarterly analysis of 5 years shows Sarepta Therapeutics' Shares Outstanding (Weighted Average) stood at $87.1 million in 2021, then climbed by 0.81% to $87.8 million in 2022, then increased by 6.57% to $93.5 million in 2023, then rose by 2.11% to $95.5 million in 2024, then grew by 2.46% to $97.7 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $97.7 million in Q3 2025, compared to $98.3 million in Q2 2025 and $97.0 million in Q1 2025.